Chair: Claire de Oliveira (Scientist, CAMH)
The main tasks of the Data Working Group are to determine data availability and accessibility in each jurisdiction, and potential health or economic outcomes that can be measured from available data sources, such as survival, adverse events, patient-reported outcomes, resource utilization and costs. In order to develop a framework that is applicable at a pan-Canadian level, there needs to be a strategy to identify and harmonize data elements from each province. Data experts from all 10 Canadian provinces are working together to explore the current data holdings and availability. These data experts will also be involved in conducting test case analyses as part of the framework development.
Riaz Alvi (Saskatchewan Cancer Agency)
Riaz Alvi is the Director of Epidemiology and Performance Measurement at the Saskatchewan Cancer Agency. He is also an Adjunct Faculty Member with the University of Saskatchewan’s College of Graduate Studies. Riaz has worked at the Saskatchewan Cancer Agency for 19 years and as Director for the last 13 years. His interests include; cancer surveillance, performance and outcomes measurement, patient reported outcomes, health equity, Real World Evidence, and cancer in indigenous populations.
Beca, J & Dai, W & Yz, R & Tran, D & Dvorani, E & Isaranuwatchai, Wanrudee & Peacock, Stuart & Alvi, R & Zz, W & Earle, Craig & Gavura, Scott & Chan, K. (2021). Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. Clinical Oncology. 10.1016/j.clon.2021.08.009.
Pataky, Reka & Beca, Jaclyn & Tran, David & Dai, Wei & Dvorani, Erind & Isaranuwatchai, Wanrudee & Peacock, Stuart & Alvi, Riaz & Cheung, Winson & Earle, Craig & Gavura, Scott & Chan, Kelvin. (2021). Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. MDM Policy & Practice. 6. 238146832110210. 10.1177/23814683211021060.
Tran, David & Coronado, A. & Sarker, S. & Alvi, R. (2019). Estimating Health Care Costs of Non-Melanoma Skin Cancer in Saskatchewan using Physician Billing Data. Current Oncology. 26. 10.3747/co.26.4557.
Reka Pataky, David A. Tran, Andrea Coronado, Riaz Alvi, Darryl Boehm, Dean A. Regier, Stuart Peacock. Cancer Drug Expenditure in British Columbia and Saskatchewan: A Trend Analysis. CMAJO. July 27, 2018. Vol. 6, No. 3. E292-E299 doi: 10.9778/cmajo.20170161
David Tran (Saskatchewan Cancer Agency)
Winson Cheung (Alberta Health Services)
Winson Y. Cheung, MD, MPH, FRCPC is a medical oncologist and a nationally and internationally recognized health services researcher and real-world data scientist. He is currently appointed as Full Professor in the Departments of Oncology, Medicine, and Community Health Sciences at the University of Calgary where he is also the Provincial Director of Health Services Research. Prior to his leadership recruitment to Calgary in 2017, he worked at BC Cancer in Vancouver for 7 years.
Dr. Cheung received his medical degree at the University of British Columbia, medical oncology subspecialty training at the University of Toronto and subsequently obtained a Masters of Public Health degree at Harvard University. He specializes in the management of gastrointestinal malignancies. He is the recipient of numerous accolades, including the National Cancer Institute of Canada Dorothy Lamont Award, the Canadian Cancer Trials Group Dr Ralph Meyer Award, the Novartis Oncology Canadian Investigator Mentor Award, and the Multinational Association of Supportive Care in Cancer Investigator Award. He has secured over 15 million dollars in competitive grant funding, including from CIHR and Canadian Cancer Society. He has also been invited to be a reviewer on national and international grant panels as well as a member on scientific program committees for the American Society of Clinical Oncology and the Canadian Cancer Research Alliance.
Dr. Cheung’s primary research interest is using big data for health services and outcomes research as well as generating real-world evidence across all tumor sites. His projects focus on understanding the interplay of various patient, physician, and system level factors that drive practice patterns in the population-based setting and learning how costs and processes can be modified to better inform care. The overarching goal of his work is to ensure that cancer care is appropriately accessed and delivered to patients in an equitable and effective manner. His own research and those of his trainees appear frequently in high impact scientific journals. To date, he has published more than 175 peer-reviewed manuscripts. He enjoys mentoring trainees, many of whom have proceeded to develop successful academic careers. Over two dozen of his trainees have received ASCO Merit Awards and additional grants since 2010.
Philip Ding (Alberta Health Services)
Jeff Dowden (Eastern Health)
Jeff Dowden is a clinical epidemiologist with Cancer Care Program, Eastern Health, St. John’s NL. Jeff has over 15 years of relevant experience in the area of health systems data, health analytics and large-scale heath data projects, specifically in the area of cancer care. As an epidemiologist with formal training in applied statistics, Jeff has extensive knowledge in epidemiological designs, analysis of complex data, and statistical modeling, as well as experience working with complex data repositories and the ability to transform and integrate data through technical expertise with linkages and assisting in building data products used for evidence-based decision making purposes. Jeff is an active member of the global cancer surveillance community and chairs a number of committees including the Canadian Cancer Registry Data Use and Publications Committee and the North American Association of Central Cancer Registries (NAACCR) Research and Data Use steering committee. Jeff’s research interest include cancer epidemiology and surveillance; and machine learning using administrative cancer data.
Dai, W.F.; de Oliveira, C.; Blommaert, S.; Pataky, R.E.; Tran, D.; Aurangzeb, Z.; Kendell, C.; Folkins, C.; Somayaji, C.; Dowden, J.; Cheung, W.; Strumpf, E.; Beca, J.M.; McClure, C.; Urquhart, R.; McDonald, J.T.; Alvi, R.; Turner, D.; Peacock, S.; Denburg, A.; Mercer, R.E.; Muñoz, C.; Parmar, A.; Tadrous, M.; Takhar, P.; Chan, K.K.W.; on behalf of the CanREValue Collaboration. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group. Curr. Oncol. 2022, 29, 2046-2063. https://doi.org/10.3390/curroncol29030165
Lyratzopoulos Y., McPhail, S, Dowden J, ICBP Members Team. Risk factors and prognostic implications of diagnosis of cancer as an emergency: An International Cancer Benchmarking Partnership (ICBP) comparative study on 857,080 patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung and ovarian cancer across 14 international jurisdictions. Lancet Oncology 2021, Accepted.
Asghari S, Boyd S, Blackmore J, Hurley O, Knight J, Kelly D, Burt K, Pittman B, Gilbert L, Dowden J. Developing a database with sensitive health information, a profile of people living with HIV in Newfoundland and Labrador. IJPDS 2020, 5(1). doi: https://doi.org/10.23889/ijpds.v5i1.1144
Zuijdwijk CS, Pardy SA, Dowden JJ, Dominic AM, Bridger T, Newhook LA. The mSCOFF for Screening Disordered Eating in Pediatric Type 1 Diabetes. Diabetes Care 2014 Feb; 37(2): e26-e27. https://doi.org/10.2337/dc13-1637.
Watkins KE, Way CY, Gregory DM, LeDrew HM, Ludlow VC, Esplen MJ, Dowden JJ, Cox JE, Fitzgerald GW, Parfrey PS. Development and preliminary testing of the psychosocial adjustment to hereditary diseases scale. BMC Psychol. 2013 Apr 30;1(1):7. doi: 10.1186/2050-7283-1-7. eCollection 2013.
Haiyan Wang (Newfoundland and Labrador Centre for Health Information)
Kelvin Chan (Sunnybrook Research Institute)
Dr. Kelvin Chan is a medical oncologist at the Sunnybrook Odette Cancer Centre, an associate professor at the University of Toronto, and an associate scientist at the Sunnybrook Research Institute. He specializes in GI oncology and head and neck oncology.
As a clinical epidemiologist and biostatistician, Dr. Chan’s research interests include health services research, health technology assessment, meta-analysis including network meta-analysis, cost-effectiveness analyses, and statistical methods research in health economics. He is co-director at the Canadian Centre for Applied Research in Cancer Control (ARCC), funded by the Canadian Cancer Society (CCS).
Professionally, Dr Chan has an interest in cancer drug reimbursement related issues. He is a member of multiple provincial and national committees related to cancer drug assessments and recommendations including the Committee to Evaluate Drug (CED) and the Ontario Steering Committee of Cancer Drugs (OSCCD). He is also the clinical lead for the Provincial Drug Reimbursement Programs (PDRP) at Ontario Health-Cancer Care Ontario (OH-CCO).
- Dai WF, de Oliveira C, Blommaert S, Pataky RE, Tran D, Aurangzeb Z, Kendell C, Folkins C, Somayaji C, Dowden J, Cheung W, Strumpf E, Beca JM, McClure C, Urquhart R, McDonald JT, Alvi R, Turner D, Peacock S, Denburg A, Mercer RE, Muñoz C, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group. Curr Oncol. 2022 Mar 17;29(3):2046-2063. doi: 10.3390/curroncol29030165. PMID: 35323365; PMCID: PMC8947246.
- Beca JM, Dai WF, Pataky RE, Tran D, Dvorani E, Isaranuwatchai W, Peacock S, Alvi R, Cheung WY, Earle CC, Gavura S, Chan KKW. Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. Clin Oncol (R Coll Radiol). 2022 Jan;34(1):e7-e17. doi: 10.1016/j.clon.2021.08.009. Epub 2021 Aug 26. PMID: 34456106.
- Dai WF, Craig E, Fraser B, Chambers A, Mai H, Brown MB, Earle CC, Evans WK, Geirnaert M, Taylor M, Trudeau M, Sperber D, Beca JM, Denburg A, Mercer RE, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration. Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise. Curr Oncol. 2021 Nov 12;28(6):4645-4654. doi: 10.3390/curroncol28060392. PMID: 34898572; PMCID: PMC8628679.
- Beca JM, Walsh S, Raza K, Hubay S, Robinson A, Mow E, Keech J, Chan KKW. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada. BMC Cancer. 2021 Oct 29;21(1):1162. doi: 10.1186/s12885-021-08746-z. PMID: 34715804; PMCID: PMC8556902.
- Dai WF, Beca JM, Croxford R, Isaranawatchai W, Menjak IB, Petrella TM, Mittmann N, Earle CC, Gavura S, Hanna TP, Chan KKW. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada. BMC Cancer. 2020 Apr 15;20(1):304. doi: 10.1186/s12885-020-06798-1. PMID: 32293341; PMCID: PMC7158109.
- Dai WF, Beca JM, Nagamuthu C, Liu N, de Oliveira C, Earle CC, Trudeau M, Mercer RE, Chan KKW. Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer. JAMA Netw Open. 2022 Feb 1;5(2):e2145460. doi: 10.1001/jamanetworkopen.2021.45460. PMID: 35226087; PMCID: PMC8886524.
- Dai WF, Beca JM, Nagamuthu C, Liu N, de Oliveira C, Earle CC, Trudeau M, Chan KKW. Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer. JAMA Oncol. 2022 Feb 24:e218049. doi: 10.1001/jamaoncol.2021.8049. Epub ahead of print. PMID: 35201264; PMCID: PMC8874900.
- Chan K, Nam S, Evans B, de Oliveira C, Chambers A, Gavura S, Hoch J, Mercer RE, Dai WF, Beca J, Tadrous M, Isaranuwatchai W. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. BMJ Open. 2020 Jan 7;10(1):e032884. doi: 10.1136/bmjopen-2019-032884. PMID: 31915169; PMCID: PMC6955501.
Jaclyn Beca (Ontario Health)
Caroline Muñoz (Ontario Health)
Wei Fang Dai (University of Toronto)
Ted McDonald (University of New Brunswick)
Ted McDonald is a Professor in the Department of Political Science at the University of New Brunswick in Fredericton. He holds a Ph.D. in Economics from the University of Melbourne, Australia. He is the founding Director of the NB Institute for Research, Data and Training, New Brunswick’s only provincial administrative data centre. He is the Chair of the Canadian Research Data Centre Network Academic Council, a member of the CRDCN Board, and the Academic Director of the NB Statistics Canada Research Data Centre. Dr. McDonald is also on the executive committee of Health Data Research Network Canada and is the New Brunswick lead of the Maritime SPOR SUPPORT Unit (MSSU). His main areas of research include the health status and health services use of immigrants and other subpopulations, socioeconomic determinants of cancer and other chronic diseases, and immigrant retention and mobility. Dr. McDonald is a UNB research scholar for 2020-22 and previously held that title in 2012-14. In 2019 he was co-winner of the Mike McCracken award for Economics Statistics, awarded by the Canadian Economics Association.
Kuta V, D Forner, J Azzi, D Curry, C Noel, K Munroe, M Bullock, JT McDonald, S Johnson-Obaseki, S Taylor, M Rigby, J Trites and M Corsten (2021) Treatment choices in managing Bethesda III and IV thyroid nodules: a Canadian multi-institutional study, OTO Open, accepted for publication. https://pubmed.ncbi.nlm.nih.gov/34250424/
Singh, S, JT McDonald, G Ilie and A Adisesh (2020) An examination of the association between lifetime history of prostate and pancreatic cancer diagnosis and occupation in a population sample of Canadians, PLOS ONE. https://doi.org/10.1371/journal.pone.0227622
Lebo, N., D. Khalil, D., A Balram, M Holland, M Corsten, JT McDonald and S Johnson-Obaseki (2019) Influence of socioeconomic status on stage at presentation of laryngeal cancer in the United States. Otolaryngology Head and Neck Surgery, 161(5), 800-806. https://doi.org/10.1177/0194599819856305
McDonald, JT, M Farnworth and Z Liu (2017) Cancer and the healthy immigrant effect: a statistical analysis of cancer diagnosis using a linked Census-cancer registry administrative database. BMC Public Health. 17:296. https://doi.org/10.1186/s12889-017-4190-2
McDonald, JT, Z Liu and Y Wang (2017) Participation and Retention in the breast cancer screening program in New Brunswick Canada. Preventive Medicine Reports. 6: 2014-220. http://dx.doi.org/10.1016/j.pmedr.2017.03.015
Chandy Somayaji (University of New Brunswick)
Chris Folkins (University of New Brunswick)
Stuart Peacock (BC Cancer)
Stuart Peacock holds the Leslie Diamond Chair in Cancer Survivorship and is a Professor in the Faculty of Health Sciences, Simon Fraser University. He is currently Co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC is a pan-Canadian research centre providing interdisciplinary leadership in health economics, services, policy and ethics research. Stuart is also a Distinguished Scientist in Cancer Control Research at the BC Cancer Agency, a member of the Board of Directors of the Canadian Agency for Drugs and Technologies in Health, and past President of the International Society on Priorities in Health Care. He has held university positions in Canada, Australia and the UK. Over the past 20 years, Stuart’s main research interests have focused on research into developing more effective cancer services, making health system funding decisions fairer and more transparent, and improving the quality of life of cancer patients and survivors.
Pataky RE, Beca J, Tran D, Dai WF, Dvorani E, Isaranuwatchai W, Peacock S, Alvi R, Cheung WY, Earle CC, Gavura S, Chan KKW. Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. MDM Policy Pract. 2021 Jun 19;6(1):23814683211021060. doi: 10.1177/23814683211021060. PMID: 34212111; PMCID: PMC8216386.
Raymakers AJN, Regier DA, Peacock SJ. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review. Cancer. 2020 Jan 1;126(1):148-155. doi: 10.1002/cncr.32455. Epub 2019 Sep 23. PMID: 31544234.
De Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KK, Cheung WY, Hoch JS, Peacock S, Krahn MD. Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. Healthc Policy. 2017 Feb;12(3):95-108. PMID: 28277207; PMCID: PMC5344366.
Pataky RE, Cheung WY, de Oliveira C, Bremner KE, Chan KK, Hoch JS, Krahn MD, Peacock SJ. Population-based trends in systemic therapy use and cost for cancer patients in the last year of life. Curr Oncol. 2016 Feb;23(Suppl 1):S32-41. doi: 10.3747/co.23.2946. Epub 2016 Feb 29. PMID: 26985144; PMCID: PMC4780587.
Cromwell I, Ferreira Z, Smith L, van der Hoek K, Ogilvie G, Coldman A, Peacock SJ. Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis. Curr Oncol. 2016 Feb;23(Suppl 1):S14-22. doi: 10.3747/co.23.2914. Epub 2016 Feb 29. PMID: 26985142; PMCID: PMC4780585.
Reka Pataky (BC Cancer)
Erin Strumpf (McGill University)
Erin Strumpf, PhD, is an Associate Professor in the Department of Economics and the Department of Epidemiology, Biostatistics and Occupational Health at McGill University. She is a William Dawson Scholar and held two Chercheur boursier career awards from the Fonds de recherche du Québec – Santé. Prof. Strumpf is a founding member of McGill’s Public Policy and Population Health Observatory (3PO). She received her PhD in Health Policy from Harvard University and her BA from Smith College.
Prof. Strumpf’s research in health economics evaluates the impacts of policy and clinical interventions on population health, health inequalities, and health care system performance. She uses methods for causal inference, principally quasi-experimental designs, to estimate the effects of interventions in real-world settings and actively collaborates with decision makers to generate relevant, usable knowledge to improve population health and health care system performance. She has presented her work to provincial ministries of health and of finance in Canada, and to policymakers in France and the United States.
Boily G, Guédon AC, Golo KT, Qureshi S, Lehuédé C, Strumpf E, 2021. « Création et caractérisation d’une cohorte québécoise de patients atteints d’un cancer du poumon à l’aide de données clinico-administratives », État de pratiques: Institut national d’excellence en santé et en services sociaux (INESSS), Québec, Qc. 152p.
Blair A, Gauvin L, Strumpf E, Datta GD, 2020. “Impact of organized colorectal cancer screening programs on screening uptake and screening inequalities: A study of systematic- and patient-reliant programs in Canada” Journal of Cancer Policy, June; 24: 100229.
Diop M, Strumpf EC, Datta GD, 2018. “Measuring colorectal cancer incidence: the performance of an algorithm using administrative health data,” BMC Medical Research Methodology, May; 18:38.
Kadiyala S and Strumpf E, 2016. “How Effective is Population-Based Cancer Screening? Regression Discontinuity Estimates from the U.S. Guideline Screening Initiation Ages”, Forum for Health Economics & Policy, 19(1), 87-139.
Smith LM, Strumpf EC†, Kaufman JS, Lofters A, Schwandt M, Levesque LE, 2015 “The Early Benefits of Human Papillomavirus Vaccination on Cervical Dysplasia and Anogenital Warts,” Pediatrics, 135(5): e1131-e1140, Apr.
Nicole Mittmann (CADTH)
Dr. Nicole Mittmann is the Chief Scientist and Vice President of Evidence Standards at the Canadian Agency for Drugs and Technologies in Health (CADTH). At CADTH, Nicole is leading a team conducting health economics, scientific reviews and information services. Other initiatives include patient engagement and real-world evidence. Formerly, the Chief Research Officer at Cancer Care Ontario (CCO), the provincial cancer agency in Ontario she constructed and implemented the first strategy and framework for research at the organization.
In her academic capacity, Dr. Mittmann holds a faculty position as an Assistant Professor at the University of Toronto in the Department of Pharmacology and Toxicology and is an Associate Scientist at Sunnybrook Health Sciences Centre. She has conducted and collaborated on notable research in the areas of economic evaluations, outcomes research and drug/patient safety. Research methodologies include the examination of large databases, economic methodologies and decision analysis. She remains an active researcher, with more than 170 peer-reviewed journal articles.
Most recently, she has been funded by Genome Quebec to examine the cost-effectiveness of breast cancer genetic tests and the Ontario Institute for Cancer Research/Cancer Care Ontario to determine the burden of cancer from a Canadian health system perspective and the development of costing algorithms for chemotherapy and radiation therapy.
Dr. Mittmann is also the co-chair of the Committee on Economic Analysis (CEA) at the Canadian Cancer Trials Group (CCTG). Responsibilities include embedding economic parameters in clinical trials, economic evaluations and guideline development. She was the lead author and investigator on the establishment of economic guidelines for oncology products in partnership with CCTG and the Canadian Agency for Drugs and Technologies in Health (CADTH).
Donna Turner (CancerCare Manitoba)
Zeb Aurangzeb (CancerCare Manitoba)
Robin Urquhart (Dalhousie University)
Cynthia Kendell (Dalhousie University)
Lynn Lethbridge (Dalhousie University)
Kim Vriends (Health PEI)
Carol McClure (Health PEI)
Do you have any questions, comments, or suggestions regarding the content of this page? If so, please contact us at CanREValue@cc-arcc.ca